India’s pharmaceutical exports reached $30.4 billion in FY 2025. Learn what’s driving this growth—FDF exports, global demand, affordable generic drugs, emerging markets, and more.
AstraZeneca’s recent announcement of the launch of eculizumab in India marks a significant milestone in the treatment of rare diseases. For patients suffering from ultra-rare, life-threatening disorders such as paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS), this launch brings hope to the Indian medical community for access to long-awaited therapies. Regulatory Approval […]
Learn how to reduce the risk of heart attack naturally with the best heart health tips. Simple changes in lifestyle, diet and habits can protect your heart.
Learn how personalized medicine is transforming healthcare with tailored treatments, better outcomes and innovative solutions from S V Healthcare.
S V Healthcare is expanding into emerging pharma markets in 2025. Discover key opportunities, challenges, and strategies for success.
Biocon Biologics has received UK MHRA approval for denosumab biosimilars Vevzuo and Avefraxi, expanding its global biosimilar footprint in 2025.
India’s pharma exports grew by 9% in FY 2024-25, higher than the global average. Find out the key drivers, trends and future outlook in this pharma export report.
Discover how tariffs impact the pharma industry globally. Learn about global trade challenges and how S V Healthcare adapts to changing export scenarios.
India’s nutraceutical market is on the verge of a big leap, expected to reach US$18 billion by 2025. For pharma exporters, this is not just a figure, it’s a signal to take action. As health-conscious consumers drive demand for food supplements and functional wellness products, companies like S V Healthcare, India’s best pharmaceutical company, are […]
